hCCR8(2)

品系全名

C57BL/6Smoc-Ccr8em3(hCCR8)/Smoc

目錄號(hào)

NM-HU-2000054

品系狀態(tài)

胚胎凍存

導(dǎo)出PDF

基因信息

基因名
CCR8

基因曾用名

Cmkbr8

NCBI ID

MGI ID

Ensembl ID

Pubmed

人類同源基因

CCR8

品系描述

通過(guò)同源重組，將小鼠基因Ccr8進(jìn)行人源化修飾。與此相似的品系還有hCCR8(NM-HU-190053)，詳細(xì)信息請(qǐng)咨詢技術(shù)顧問(wèn)。
應(yīng)用領(lǐng)域：免疫治療；藥物篩選

驗(yàn)證數(shù)據(jù)

image.png

Fig1. Expression characterization of CCR8 humanized mouse.?

(A) Human CCR8 expression on activated splenic CD4+, CD8+ and Treg cells upon anti-mCD3/mCD28 stimulation in hCCR8 mice; (B) Statistics of T cell populations in hCCR8 mice.

image.png

Fig2. The anti-hCCR8 therapeutic antibody shows potent antitumor efficacy in hCCR8 mice.?

(A) and (B) in vivo antitumor response of anti-hCCR8 in hCCR8 mice bearing MC38 tumor.

image.png

Fig3. In vivo antitumor responses of anti-hCCR8 alone or in combination with anti-PD-1 in hCCR8 knockin mice engrafted with MC38 tumor.?

(A) Mean tumor growth curves upon treatment; (B) Individual tumor growth curves upon treatment.

image.png

Fig4. In vivo efficacy study in CCR8 humanized mice grafted with MC38 tumor model. JTX-1811 can inhibit the growth of MC38 xenografts (A) without significant effect on the body weight of CCR8 humanized mice (B).(provided by partner)

你也可能感興趣

Tamoxifen誘導(dǎo)Cre-ERT2小鼠 使用指南

Cre-ERT2在無(wú)Tamoxifen誘導(dǎo)的情況下，在細(xì)胞質(zhì)內(nèi)處于無(wú)活性狀態(tài)；當(dāng)Tamoxifen誘導(dǎo)后，Tamoxifen的代謝產(chǎn)物4-OHT（雌激素類似物）與ERT結(jié)合，可使Cre-ERT2進(jìn)核發(fā)揮Cre重組酶活性。

查看
【小鼠大學(xué)問(wèn)】基因工程小鼠的命名規(guī)則

常見(jiàn)的基因工程小鼠可以分為兩種命名方式，包括基因定點(diǎn)修飾的小鼠命名，比如：敲除、敲入、點(diǎn)突變等等，和隨機(jī)轉(zhuǎn)基因的小鼠命名。

查看